Nontuberculous Mycobacterial Infections Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Nontuberculous Mycobacterial Infections Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Nontuberculous Mycobacterial Infections Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Nontuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Nontuberculous Mycobacterial Infections Market by downloading the comprehensive report from DelveInsight @ Nontuberculous Mycobacterial Infections Treatment Market Size
Key Takeaways from the Nontuberculous Mycobacterial Infections Market Report
- In October 2024:- MannKind Corporation- This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT). Randomized, double-blind, placebo-controlled study (Part A) designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT). The primary objective of this study will be to compare the efficacy of Clofazimine Inhalation Suspension versus placebo as assessed by the co-primary endpoints, sputum culture conversion and change in Quality of Life-Bronchiectasis Respiratory Symptoms Score (QoL-B RSS).
- The growth of the NTM infections market is expected to be primarily driven by an expanding patient population, and the launch of emerging therapies.
- As per the study conducted in the US in 2020, the respective yearly prevalence estimates for NTM lung disease from 2008 to 2015 in people younger than 65 years of age increased from 2.87 to 4.10 per 100,000 persons compared with an increase in people aged 65 years or older from 30.27 to 47.48 per 100,000 persons.
- A study of gender susceptibility to mycobacterial infections in patients found that the prevalence of NTM was 1.1–1.6- fold higher among women relative to men across the different sites in the USA in 2015.
- The leading Nontuberculous Mycobacterial Infections Companies such as AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, and others
- Promising Nontuberculous Mycobacterial Infections Therapies such as ALIS, Azithromycin, Ethambutol, Delpazolid, SPR720 500 mg, RHB-204, and others.
Gain a competitive edge in the Nontuberculous Mycobacterial Infections Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Nontuberculous Mycobacterial Infections Treatment Drugs
Nontuberculous Mycobacterial Infections Epidemiology Segmentation
- Total Nontuberculous Mycobacterial Infections Prevalent Cases
- Total Nontuberculous Mycobacterial Infections Diagnosed Prevalent Cases
- Nontuberculous Mycobacterial Infections Gender-specific Diagnosed Prevalent Cases
- Nontuberculous Mycobacterial Infections Species-specific Diagnosed Prevalent Cases
- Nontuberculous Mycobacterial Infections Type-specific Diagnosed Prevalent Cases
- Nontuberculous Mycobacterial Infections Severity-specific Diagnosed Prevalent Cases
- Nontuberculous Mycobacterial Infections Treatable Cases
Nontuberculous Mycobacterial Infections Market Insights
Treatment options for NTM (non-tuberculous mycobacteria) lung disease typically involve a combination of antibiotics tailored to the specific strain of NTM involved and the patient’s overall health. Fluoroquinolone antibiotics like ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, and ofloxacin are commonly recommended for treatment. Treatment for NTM Infections is often prolonged, lasting for months to years, and requires careful monitoring for efficacy and potential side effects. Additionally, patients may benefit from adjunctive therapies such as airway clearance techniques, nutritional support, and pulmonary rehabilitation to manage symptoms and improve quality of life.
Discover key developments and opportunities in the Nontuberculous Mycobacterial Infections Market. Click here to learn more from DelveInsight’s latest report @ Nontuberculous Mycobacterial Infections Market Size
Nontuberculous Mycobacterial Infections Treatment Market
Nontuberculous mycobacteria (NTM) infections refer to any diseases caused by bacteria belonging to the genus Mycobacterium, excluding those that cause tuberculosis (M. tuberculosis complex) or leprosy/Hansen’s disease (M. leprae). According to the American Lung Association, Nontuberculous mycobacteria naturally inhabit soil, water, and dust worldwide. MAC is the predominant type of NTM bacteria in the US, causing the majority of NTM lung disease cases in the country. There are two forms of NTM lung disease based on disease progression. Nodular bronchiectatic, which is a less progressive NTM disease, affects older women without a smoking history, causing airway inflammation and scarring, leading to recurrent respiratory infections like bronchitis and pneumonia. Cavitary NTM disease, which is more progressive and prevalent in smokers with existing lung conditions, results in lung tissue scarring, fibrosis, and cavity formation, potentially leading to respiratory failure.
Nontuberculous Mycobacterial Infections Marketed Drugs
- ARIKAYCE (amikacin liposome inhalation suspension): Insmed
ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed’s proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH.
Nontuberculous Mycobacterial Infections Emerging Drugs
- Epetraborole: AN2 Therapeutics
- MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation
- SPR720 (Fobrepodacin): Spero Therapeutics
Nontuberculous Mycobacterial Infections Market Outlook
Nontuberculous Mycobacterial Infections treatment is challenging and requires prolonged, multidrug regimens that are often tailored to the specific NTM species and the site of infection. The management of these infections is complicated by the intrinsic resistance of many NTM species to standard antibiotics, necessitating the use of specialized and often costly medications. Consequently, NTM infections represent a significant and growing market within the pharmaceutical and healthcare industries, with ongoing research efforts focused on developing more effective diagnostic tools and novel therapeutics to improve patient outcomes.
Download DelveInsight’s Nontuberculous Mycobacterial Infections Market report today and stay ahead in this rapidly evolving field. @ Nontuberculous Mycobacterial Infections Clinical Trials
Scope of the Nontuberculous Mycobacterial Infections Market Report
- Coverage- 7MM
- Nontuberculous Mycobacterial Infections Companies- AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, and others
- Nontuberculous Mycobacterial Infections Therapies- ALIS, Azithromycin, Ethambutol, Delpazolid, SPR720 500 mg, RHB-204, and others.
- Nontuberculous Mycobacterial Infections Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Nontuberculous Mycobacterial Infections Unmet Needs, KOL’s views, Analyst’s views, Nontuberculous Mycobacterial Infections Market Access and Reimbursement
Download the report to understand which factors are driving Nontuberculous Mycobacterial Infections Market Trends @ Nontuberculous Mycobacterial Infections Market Trends
Table of Content
1. Key Insights
2. Report Introduction
3. NTM Infection Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
11. Emerging Drugs
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/